Acute Radiation Syndrome - Pipeline Insight, 2025

This “Acute Radiation Syndrome - Pipeline Insight, 2025” report provides comprehensive insights about 3+ companies and 5+ pipeline drugs in Acute Radiation Syndrome pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Acute Radiation Syndrome: Understanding

Acute Radiation Syndrome: Overview

Acute Radiation Syndrome (ARS) refers to a collection of symptoms resulting from significant exposure to ionizing radiation, which can cause severe damage to various organ systems and potentially lead to death. As defined by the National Council on Radiation Protection and Measurements, ARS encompasses a range of effects that can manifest within hours or months after exposure, depending on the radiation dose. The severity of symptoms varies based on the level of radiation absorbed, ranging from mild nausea to life-threatening organ failure. Proper management of ARS requires careful planning at governmental, local, and medical levels to ensure effective treatment and the efficient use of limited resources.

Symptoms of Acute Radiation Syndrome (ARS) can begin immediately after exposure or develop over days, weeks, or even months, depending on the severity of the radiation dose. The initial signs often include weakness, fatigue, nausea, and vomiting. As the condition progresses, more severe symptoms may manifest, such as vomiting blood, rectal bleeding, diarrhea, fever, confusion, and hair loss. Additionally, affected individuals may experience tenderness, skin discoloration, swelling, or a burning sensation. These symptoms unfold in stages, corresponding to the three ARS syndromes - hematopoietic, gastrointestinal, and cardiovascular/central nervous system - each characterized by progressively worsening complications. In severe cases, rapid deterioration of organ systems may occur, leading to multi-organ failure. The timing and severity of symptoms can vary based on the radiation dose, and prompt medical intervention is crucial for improving outcomes. Ultimately, the prognosis depends on the radiation dose received and the effectiveness of the treatment provided.

Acute Radiation Syndrome (ARS) can result from either direct exposure to ionizing radiation or contamination by radioactive materials. Direct exposure may occur through events like a nuclear blast, while contamination can happen through the ingestion of radioactive food or water, or skin contact with nuclear material. ARS is classified into three syndromes based on the affected systems: hematopoietic, gastrointestinal, and cardiovascular/neurological. Each syndrome requires a different radiation dose to manifest symptoms, and the timing of symptom onset is divided into three phases: prodromal, latent, and manifest. The severity and progression of ARS depend on the radiation dose, the timing of symptom onset, and which syndrome is triggered by the exposure.

The treatment and management of Acute Radiation Syndrome (ARS) focus on minimizing exposure and providing supportive care to enhance survival. Decontamination is critical, starting with the removal of contaminated clothing to reduce exposure by up to 80%, followed by bathing patients with a history of contamination. In cases of life-threatening injuries, decontamination is performed, but priority is given to surgical and trauma emergencies within the first 24 hours to prevent complications from radiation exposure. Fluid management, infection control, and early administration of antibiotics are essential, along with pain management for burns and injuries. To prevent thyroid cancer, potassium iodide should be given to children and pregnant women, and breastfeeding mothers should be encouraged to stop if possible. In moderate exposures, cytokines and colony-stimulating factors may be used, and bone marrow transplants may be considered for large dose exposures, though this remains controversial. Chelating agents should only be used after consulting a nuclear specialist. Psychological support, particularly for displaced children, is also vital given the emotional toll of radiation exposure.

'Acute Radiation Syndrome- Pipeline Insight, 2025' report outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Acute Radiation Syndrome pipeline landscape is provided which includes the disease overview and Acute Radiation Syndrome treatment guidelines. The assessment part of the report embraces, in depth Acute Radiation Syndrome commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Acute Radiation Syndrome collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Report Highlights

The companies and academics are working to assess challenges and seek opportunities that could influence Acute Radiation Syndrome R&D. The therapies under development are focused on novel approaches to treat/improve Acute Radiation Syndrome.

Acute Radiation Syndrome Emerging Drugs Chapters

This segment of the Acute Radiation Syndrome report encloses its detailed analysis of various drugs in different stages of clinical development, including Phase III, II, I, Preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Acute Radiation Syndrome Emerging Drugs

Avoplacel: Pluri

Avoplacel (PLX-R18) is designed to treat bone marrow that is unable to produce enough blood cells due to a variety of causes including acute radiation syndrome (ARS), certain cancers or cancer treatments, or immune-mediated bone marrow failure. Further preclinical data from trials have shown that PLX-R18 cells secrete a range of specific proteins that trigger the regeneration of bone marrow hematopoietic cells, thereby supporting the recovery of blood cell production. The U.S. Food and Drug Administration (FDA) has also granted an Orphan Drug Designation for its PLX-R18 cell therapy for the prevention and treatment of Acute Radiation Syndrome (ARS). Currently, the drug is in Phase II stage of its development for the treatment of Acute Radiation Syndrome.

BIO 300 Oral Suspension: Humanetics Corporation

BIO 300 is a novel therapeutic agent developed by Humanetics Pharmaceuticals for the treatment of Acute Radiation Syndrome (ARS). The active ingredient in BIO 300 is genistein, a naturally occurring isoflavone that acts as a potent modulator of various biological pathways. Its mechanism of action involves multiple processes, including the enhancement of DNA repair, modulation of inflammation, and protection of normal tissues from radiation damage while sparing tumor cells. This selective radioprotective effect is crucial in mitigating the harmful consequences of radiation exposure. BIO 300 has received Orphan Drug Designation by the FDA and is being developed as a medical countermeasure to improve survival and reduce morbidity in individuals exposed to myelosuppressive doses of radiation. Currently, the drug is in Phase I stage of its development for the treatment of Acute Radiation Syndrome.

Acute Radiation Syndrome: Therapeutic Assessment

This segment of the report provides insights about the different Acute Radiation Syndrome drugs segregated based on following parameters that define the scope of the report, such as:

Major Players in Acute Radiation Syndrome

• There are approx. 3+ key companies which are developing the therapies for Acute Radiation Syndrome. The companies which have their Acute Radiation Syndrome drug candidates in the most advanced stage, i.e. Phase II include, Pluri.

Phases

The report covers around 5+ products under different phases of clinical development like

• Late stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates

Route of Administration

Acute Radiation Syndrome pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

• Oral
• Intravenous
• Subcutaneous
• Parenteral
• Topical

Molecule Type

Products have been categorized under various Molecule types such as

• Recombinant fusion proteins
• Small molecule
• Monoclonal antibody
• Peptide
• Polymer
• Gene therapy

Product Type

Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Acute Radiation Syndrome: Pipeline Development Activities

The report provides insights into different therapeutic candidates in Phase III, II, I, preclinical and discovery stage. It also analyses Acute Radiation Syndrome therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Acute Radiation Syndrome drugs.

Acute Radiation Syndrome Report Insights

• Acute Radiation Syndrome Pipeline Analysis
• Therapeutic Assessment
• Unmet Needs
• Impact of Drugs

Acute Radiation Syndrome Report Assessment

• Pipeline Product Profiles
• Therapeutic Assessment
• Pipeline Assessment
• Inactive drugs assessment
• Unmet Needs

Key Questions

Current Treatment Scenario and Emerging Therapies:

• How many companies are developing Acute Radiation Syndrome drugs?
• How many Acute Radiation Syndrome drugs are developed by each company?
• How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Acute Radiation Syndrome?
• What are the key collaborations (Industry-Industry, Industry-Academia), Mergers and acquisitions, licensing activities related to the Acute Radiation Syndrome therapeutics?
• What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
• What are the clinical studies going on for Acute Radiation Syndrome and their status?
• What are the key designations that have been granted to the emerging drugs?

Key Players

• Pluri
• Humanetics Corporation
• RedHill Biopharma Ltd.

Key Products

• Avoplacel
• BIO 300 Oral Suspension
• Opaganib

This product will be delivered within 2 business days.